Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244793 | 0.85 | MAOA (0.57) | SLC6A2SLC6A4SLC6A3MAOAMAOB | |
| SCHEMBL2616785 | 0.83 | MAOA (0.61) | SLC6A2SLC6A4SLC6A3MAOAMAOB | |
| SCHEMBL14500169 | 0.81 | DRD1 (0.50) | SLC6A2SLC6A4SLC6A3MAOAMAOB | |
| SCHEMBL22993028 | 0.77 | ALDH1A1 (0.44) | CYP2D6DPP8DPP9DPP7KCNH2 | |
| SCHEMBL23010788 | 0.77 | HRH1 (0.42) | SLC6A2SLC6A4SLC6A3CYP2D6ALDH1A1 | |
| SCHEMBL12706078 | 0.76 | MAOA (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6MAOA | |
| SCHEMBL11974589 | 0.76 | DPP8 (0.39) | SLC6A2SLC6A4SLC6A3CYP2D6DPP8 | |
| SCHEMBL18999610 | 0.76 | DPP8 (0.39) | SLC6A2SLC6A4SLC6A3DPP8DPP9 | |
| SCHEMBL13961198 | 0.76 | DPP8 (0.45) | DPP8DPP9DPP7KCNH2ALDH1A1 | |
| SCHEMBL12367362 | 0.76 | KCNH2 (0.50) | SLC6A2SLC6A4SLC6A3DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400505-A1 | PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF | Bivision Pharmaceuticals, Inc (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20240231230-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM | NISSAN CHEMICAL CORPORATION (JP) | 2024-07-11 | — | — | US | disclosed |
| EP-4328225-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023239710-A1 | BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230322776-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CURZA GLOBAL, LLC. | 2023-09-07 | — | — | US | disclosed |
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CURZA GLOBAL, LLC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023164175-A2 | PROTACS OF MALT1 | TEGID THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008020306-A2 | ISOINDOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1509537-B9 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES INC (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1509537-B1 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES INC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-7229986-B2 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278987-A1 | Antimicrobial Compounds and Methods | CLPP, RPN2, MPO | SLC6A2 3103/4885SLC6A4 3472/4885SLC6A3 2786/4885 |
| US-20230322776-A1 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | QDPR, P2RY1, REN | SLC6A2 141/4885SLC6A4 256/4885SLC6A3 243/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | SLC6A2 4822/4885SLC6A4 4312/4885SLC6A3 4776/4885 |
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | SLC6A2 1446/4885SLC6A4 553/4885SLC6A3 536/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | SLC6A2 3738/4885SLC6A4 3091/4885SLC6A3 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.